Aratana Therapeutics Inc. (PETX) Stock Price Down 2.1%
Aratana Therapeutics Inc. (NASDAQ:PETX) shares fell 2.1% on Wednesday . The stock traded as low as $8.83 and last traded at $8.93, with a volume of 213,733 shares changing hands. The stock had previously closed at $9.12.
Several brokerages recently weighed in on PETX. Barclays PLC reduced their price target on Aratana Therapeutics from $15.00 to $11.00 and set an “overweight” rating for the company in a research report on Thursday, August 11th. Jefferies Group began coverage on Aratana Therapeutics in a research report on Friday, August 19th. They set a “buy” rating and a $13.00 price target for the company. Zacks Investment Research cut Aratana Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, July 28th. William Blair reiterated an “outperform” rating on shares of Aratana Therapeutics in a research report on Wednesday, August 17th. Finally, Lake Street Capital reiterated a “buy” rating and set a $15.00 price target on shares of Aratana Therapeutics in a research report on Tuesday, September 6th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $11.28.
The stock’s market capitalization is $323.34 million. The company has a 50 day moving average of $9.01 and a 200 day moving average of $6.91.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/aratana-therapeutics-inc-petx-stock-price-down-2-1.html
Aratana Therapeutics (NASDAQ:PETX) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.24 by $0.37. The business earned $38.05 million during the quarter, compared to analysts’ expectations of $15.14 million. Aratana Therapeutics had a negative return on equity of 17.53% and a negative net margin of 166.67%. During the same period last year, the firm earned ($0.23) EPS. On average, equities analysts predict that Aratana Therapeutics Inc. will post ($0.77) EPS for the current fiscal year.
In related news, insider Julia A. Stephanus sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 28th. The stock was sold at an average price of $6.25, for a total value of $187,500.00. Following the completion of the transaction, the insider now directly owns 127,503 shares of the company’s stock, valued at approximately $796,893.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Peter Steven St sold 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 9th. The shares were sold at an average price of $9.25, for a total value of $462,500.00. Following the completion of the transaction, the insider now directly owns 642,793 shares of the company’s stock, valued at $5,945,835.25. The disclosure for this sale can be found here. 6.70% of the stock is owned by insiders.
Institutional investors have recently added to or reduced their stakes in the stock. California State Teachers Retirement System increased its position in Aratana Therapeutics by 9.7% in the second quarter. California State Teachers Retirement System now owns 69,941 shares of the biopharmaceutical company’s stock valued at $442,000 after buying an additional 6,211 shares during the last quarter. Bank of New York Mellon Corp increased its position in Aratana Therapeutics by 16.7% in the second quarter. Bank of New York Mellon Corp now owns 136,864 shares of the biopharmaceutical company’s stock valued at $866,000 after buying an additional 19,590 shares during the last quarter. Tocqueville Asset Management L.P. bought a new position in Aratana Therapeutics during the second quarter valued at $209,000. Iguana Healthcare Management LLC bought a new position in Aratana Therapeutics during the first quarter valued at $1,070,000. Finally, Westend Capital Management LLC increased its position in Aratana Therapeutics by 37.2% in the first quarter. Westend Capital Management LLC now owns 123,190 shares of the biopharmaceutical company’s stock valued at $680,000 after buying an additional 33,410 shares during the last quarter. 85.56% of the stock is owned by hedge funds and other institutional investors.
Aratana Therapeutics Company Profile
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.